	US 11,814,689 B2
	Nucleic acid detection using type III CRISPR complex
Blake A. Wiedenheft, Bozeman, MT (US); Andrew Santiago-Frangos, Bozeman, MT (US); Anna A. Nemudraia, Bozeman, MT (US); and Artem A. Nemudryi, Bozeman, MT (US)
Assigned to MONTANA STATE UNIVERSITY, Bozeman, MT (US)
Filed by Montana State University, Bozeman, MT (US)
Filed on Jul. 21, 2022, as Appl. No. 17/814,097.
Claims priority of provisional application 63/320,199, filed on Mar. 15, 2022.
Claims priority of provisional application 63/320,198, filed on Mar. 15, 2022.
Claims priority of provisional application 63/224,356, filed on Jul. 21, 2021.
Prior Publication US 2023/0053573 A1, Feb. 23, 2023
Int. Cl. C12N 9/22 (2006.01); C12N 15/10 (2006.01); C12Q 1/6844 (2018.01); C12Q 1/6806 (2018.01); C12Q 1/6876 (2018.01); C12Q 1/70 (2006.01); C12Q 1/6818 (2018.01); C12Q 1/6853 (2018.01)

CPC C12Q 1/701 (2013.01) [C12Q 1/6806 (2013.01); C12Q 1/6818 (2013.01); C12Q 1/6853 (2013.01)]

22 Claims

1. A method of programmatically capturing and detecting target nucleic acid in a sample based on an engineered type III Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) complex, the method comprising:

capturing the target nucleic acid in the sample using the engineered type III CRISPR-Cas complex, the engineered type III CRISPR-Cas complex comprising: a CRISPR guide comprising a CRISPR guide sequence engineered to be complementary to the target nucleic acid;

concentrating the captured target nucleic acid to amplify detectable activity of the engineered type III CRISPR-Cas complex; and

detecting the captured and concentrated target nucleic acid based on the detectable activity of the engineered type III CRISPR-Cas complex.